Marathon Group completed a transaction, involving a purchase of 5% of ordinary registered shares of Biocom, a Stavropol pharmaceutical factory, from a minority shareholder. The transaction was made in cash, the amount is not disclosed.
Thus, the consolidated shareholding of Biocom JSC controlled by Marathon Group totals to 80.1%, and the remaining shares are held by the company's management.
"Biocom is a great asset, it's a modern efficient company that complies with strategic plans of Marathon Pharma to the fullest extent, and therefore, we are glad that we have an opportunity to increase our share in its share capital," the president of Marathon Group, Alexandr Vinokurov comments the transaction. "The minority shareholding that belongs to the company's management guarantees achievement of our common goals relating to the future development of this asset".
Biocom JSC is a modern flexible full-cycle producer, specialising in production of high quality generics. The principle of rapid change in technologies allows a very quick shift, within 24 hours, from production of one drug to another. Over the coming years, the company plans to at least double the factory's capacities (up to 26 mn packages a year) and produce five new drugs.
The latter includes Hydroxychloroquine, antimalarial drug developed by Biocom JSC registered in the State Register of Medical Drugs in May 2017. It will be launched at the market by the end of the year.
Hydroxychloroquine is included in the VED list. Currently, Biocom JSC produces 15 INNs (International Non-proprietary Name) from the VED list, and in 2017, 2.2 mn of packages of these drugs were produced.